Chronic
Idiopathic Constipation Market Research Report: By Diagnosis (Blood Tests,
Sigmoidoscopy, Colonoscopy, Balloon Expulsion Test, Anorectal Manometry),
Treatment (Drugs), End-User (Hospitals & Clinics, Diagnostic Centers) –
Global Forecast Till 2023
Market Highlights
The market in Asia Pacific is
expected to grow rapidly in the coming years. By studying and analyzing the
market, it shows that this region has a good growth potential due to increasing
unhealthy eating habits and unhygienic conditions. The other major chronic
disease found in this region is the gastric cancer.
Segmentation
The global Chronic Idiopathic Constipation Market is segmented on the basis of diagnosis, treatment,
and end-user. On the basis of diagnosis, the market is segmented into blood
tests, sigmoidoscopy, colonoscopy, balloon expulsion tests, anorectal
manometry, colonic transit study, defecography, and others. On the basis of
treatment, the market is segmented into drug and surgery. Drugs are further
segmented into acid neutralizers, laxatives and antidiarrheal, antiemetics,
antiulcer, lubiprostone (amitiza) and linaclotide (linzess), misoprostol
(Cytotec), colchicine/probenecid (Col-Probenecid) and Onabotulinumtoxin A (also
called botulinum toxin type A or Botox), and others. On the basis of end-user,
the market is segmented into hospitals, gastroenterology clinics, diagnostic
centers, and others.
Regional Analysis
The Americas dominates the global
chronic idiopathic constipation market owing to the increasing prevalence of
chronic constipation and the presence of a well-developed healthcare sector
within the region. Moreover, the increasing healthcare expenditure and the
presence of key players within regional boundaries provide a favorable
background for the market growth.
Europe is the second largest in
the global chronic idiopathic constipation market. Factors such as the
increasing availability of funds for research and a huge patient population
followed by a well-developed healthcare sector drive the market within the
region.
Asia Pacific is estimated to be
the fastest growing market for chronic idiopathic constipation. This can be
attributed to the presence of developing economies such as India and China and
a huge patient population. Moreover, the increasing healthcare expenditure and
a rapidly developing healthcare sector boost the market growth within the
region.
On the other hand, the Middle
East and Africa has the least share in the global chronic idiopathic
constipation market due to the low per capita healthcare expenditure and
stringent government policies, especially within the African region. It is
estimated that the Middle East holds a majority of the market within the Middle
Eastern and African region.
Access
Report Details @ https://www.marketresearchfuture.com/reports/chronic-idiopathic-constipation-market-5931
Key Players
Some of the key players in this
market are Actavis (U.S.), Chugai Pharmaceutical (Japan), Ferring
International Center S.A.(Switzerland), Synergy Pharmaceuticals (U.S.), Pfizer
Inc (U.S.), GlaxoSmithKline (U.K.), Sanofi (France), Bayer (Germany), Salix Pharmaceuticals
Ltd (U.S.), Sucampo Pharmaceuticals Inc (U.S.), Ironwood Pharmaceuticals
(U.S.), Progenics Pharmaceuticals (U.S.), F. Hoffmann-La Roche AG
(Switzerland), Boehringer Ingelheim GmbH (Germany), Daewoong Co. Ltd.(South
Korea), Synergy Pharmaceuticals, Inc. (U.S.), and others.
No comments:
Post a Comment